Christopher P Cannon (Christopher Cannon)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 44

Top Topics

Atrial Fibrillation

Ejection Fraction

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

Journal of the American Heart Association

Clinical cardiology

European heart journal

This page only lists publications with an associated author ORCID identifier.

Publications

Ayodele Odutayo, Francesco Cosentino, Richard E Pratley, Samuel Dagogo-Jack, Darren K McGuire, Robert Frederich, Wei Fu, Christopher P Cannon, David Z I Cherney, null null
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial. Diabetes, obesity & metabolism 26 (8) (2024)
Alexander J Blood, Lee-Shing Chang, Shahzad Hassan, Jacqueline Chasse, Gretchen Stern, Daniel Gabovitch, David Zelle, Caitlin Colling, Samuel J Aronson, Christian Figueroa, Emma Collins, Ryan Ruggiero, Emily Zacherle, Josh Noone, Carey Robar, Jorge Plutzky, Thomas Andrew Gaziano, Christopher P Cannon, Deborah J Wexler, Benjamin M Scirica
Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial. Circulation (2024)
Alexander J Blood, Lee-Shing Chang, Shahzad Hassan, Jacqueline Chasse, Gretchen Stern, Daniel Gabovitch, David Zelle, Caitlin Colling, Samuel J Aronson, Christian Figueroa, Emma Collins, Ryan Ruggiero, Emily Zacherle, Joshua Noone, Carey Robar, Jorge Plutzky, Thomas Andrew Gaziano, Christopher P Cannon, Deborah J Wexler, Benjamin M Scirica
Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial. Circulation 149 (23) (2024)
Arthur Shiyovich, Adam N Berman, Stephanie A Besser, David W Biery, Gurleen Kaur, Sanjay Divakaran, Avinainder Singh, Daniel M Huck, Brittany N Weber, Jorge Plutzky, Marcelo F Di Carli, Khurram Nasir, Christopher P Cannon, James L Januzzi, Deepak L Bhatt, Ron Blankstein
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry. Journal of the American Heart Association 13 (10) (2024)
Arthur Shiyovich, Adam N Berman, Stephanie A Besser, David W Biery, Gurleen Kaur, Sanjay Divakaran, Avinainder Singh, Daniel M Huck, Brittany N Weber, Jorge Plutzky, Marcelo F Di Carli, Khurram Nasir, Christopher P Cannon, James L Januzzi, Deepak L Bhatt, Ron Blankstein
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry. Journal of the American Heart Association 13 (10) (2024)
Arthur Shiyovich, Adam N Berman, Stephanie A Besser, David W Biery, Gurleen Kaur, Sanjay Divakaran, Avinainder Singh, Daniel M Huck, Brittany N Weber, Jorge Plutzky, Marcelo F Di Carli, Khurram Nasir, Christopher P Cannon, James L Januzzi, Deepak L Bhatt, Ron Blankstein
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry. Journal of the American Heart Association 13 (10) (2024)
Arthur Shiyovich, Adam N Berman, Stephanie A Besser, David W Biery, Gurleen Kaur, Sanjay Divakaran, Avinainder Singh, Daniel M Huck, Brittany N Weber, Jorge Plutzky, Marcelo F Di Carli, Khurram Nasir, Christopher P Cannon, James L Januzzi, Deepak L Bhatt, Ron Blankstein
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry. Journal of the American Heart Association 13 (10) (2024)
Arthur Shiyovich, Adam N Berman, Stephanie A Besser, David W Biery, Gurleen Kaur, Sanjay Divakaran, Avinainder Singh, Daniel M Huck, Brittany N Weber, Jorge Plutzky, Marcelo F Di Carli, Khurram Nasir, Christopher P Cannon, James L Januzzi, Deepak L Bhatt, Ron Blankstein
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry. Journal of the American Heart Association 13 (10) (2024)
Arthur Shiyovich, Adam N Berman, Stephanie A Besser, David W Biery, Gurleen Kaur, Sanjay Divakaran, Avinainder Singh, Daniel M Huck, Brittany N Weber, Jorge Plutzky, Marcelo F Di Carli, Khurram Nasir, Christopher P Cannon, James L Januzzi, Deepak L Bhatt, Ron Blankstein
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry. Journal of the American Heart Association (2024)
Ayodele Odutayo, Francesco Cosentino, Richard E Pratley, Samuel Dagogo-Jack, Darren K McGuire, Robert Frederich, Wei Fu, Christopher P Cannon, David Z I Cherney, null null
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial. Diabetes, obesity & metabolism (2024)
Alexander J Blood, Lee-Shing Chang, Shahzad Hassan, Jacqueline Chasse, Gretchen Stern, Daniel Gabovitch, David Zelle, Caitlin Colling, Samuel J Aronson, Christian Figueroa, Emma Collins, Ryan Ruggiero, Emily Zacherle, Joshua Noone, Carey Robar, Jorge Plutzky, Thomas Andrew Gaziano, Christopher P Cannon, Deborah J Wexler, Benjamin M Scirica
Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial. Circulation 149 (23) (2024)
Joseph M Kim, Deepak L Bhatt, Samuel Dagogo-Jack, David Z I Cherney, Francesco Cosentino, Darren K McGuire, Richard E Pratley, Chih-Chin Liu, Nilo B Cater, Robert C Frederich, James P Mancuso, Christopher P Cannon
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease. Diabetes, obesity & metabolism (2023)
Simin Gharib Lee, Alexander J Blood, Christopher P Cannon, William J Gordon, Hunter Nichols, David Zelle, Benjamin M Scirica, Naomi Deirdre Lakshmi Fisher
Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID-19 Pandemic. Journal of the American Heart Association 12 (6) (2023)
Ambarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, Christopher P Cannon, Robert C Frederich, David Z I Cherney, Samuel Dagogo-Jack, Richard E Pratley, Nilo B Cater, Ira Gantz, James P Mancuso, Darren K McGuire
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. European heart journal (2023)
Joseph M Kim, Deepak L Bhatt, Samuel Dagogo-Jack, David Z I Cherney, Francesco Cosentino, Darren K McGuire, Richard E Pratley, Chih-Chin Liu, Nilo B Cater, Robert Frederich, James P Mancuso, Christopher P Cannon
Potential for Residual Cardiovascular Risk Reduction: Eligibility for Icosapent Ethyl in the VERTIS CV Population with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Diabetes, obesity & metabolism (2023)
Samuel Dagogo-Jack, Robert Frederich, Jie Liu, Christopher P Cannon, Harry Shi, David Z I Cherney, Francesco Cosentino, Urszula Masiukiewicz, Ira Gantz, Richard E Pratley
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. The Journal of clinical endocrinology and metabolism (2023)
Samuel Dagogo-Jack, Robert Frederich, Jie Liu, Christopher P Cannon, Harry Shi, David Z I Cherney, Francesco Cosentino, Urszula Masiukiewicz, Ira Gantz, Richard E Pratley
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. The Journal of clinical endocrinology and metabolism (2023)
Suzanne V Arnold, James A de Lemos, Luke Zheng, Robert S Rosenson, Christie M Ballantyne, Shushama Alam, Deepak L Bhatt, Christopher P Cannon, Mikhail Naum Kosiborod, null null
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes, obesity & metabolism (2023)
Suzanne V Arnold, James A de Lemos, Luke Zheng, Robert S Rosenson, Christie M Ballantyne, Shushama Alam, Deepak L Bhatt, Christopher P Cannon, Mikhail Naum Kosiborod, null null
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes, obesity & metabolism (2023)
Nishant P Shah, Darren K McGuire, Christopher P Cannon, Robert P Giugliano, Yuliya Lokhnygina, Courtney B Page, Andrew M Tershakovec, Eugene Braunwald, Michael A Blazing
Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT. Journal of the American Heart Association (2023)
Simin Gharib Lee, Alexander J Blood, Christopher P Cannon, William J Gordon, Hunter Nichols, David Zelle, Benjamin M Scirica, Naomi Deirdre Lakshmi Fisher
Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID-19 Pandemic. Journal of the American Heart Association (2023)
Simin Gharib Lee, Alexander J Blood, Christopher P Cannon, William J Gordon, Hunter Nichols, David Zelle, Benjamin M Scirica, Naomi Deirdre Lakshmi Fisher
Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID-19 Pandemic. Journal of the American Heart Association 12 (6) (2023)
Chao Li, Jie Yu, Carinna Hockham, Vlado Perkovic, Brendon L Neuen, Sunil V Badve, Lauren Houston, Vivian Y J Lee, Jennifer Y Barraclough, Robert A Fletcher, Kenneth W Mahaffey, Hiddo J Lambers Heerspink, Christopher P Cannon, Bruce C Neal, Clare Arnott
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. Diabetes, obesity & metabolism 24 (10) (2022)
Nicholas A Marston, Amanda C Garfinkel, Frederick K Kamanu, Giorgio M Melloni, Carolina Roselli, Petr Jarolím, David D Berg, Deepak L Bhatt, Marc P Bonaca, Christopher P Cannon, Robert P Giugliano, Michelle L O'Donoghue, Itamar Raz, Benjamin M Scirica, Eugene Braunwald, David A Morrow, Patrick T Ellinor, Steven A Lubitz, Marc S Sabatine, Christian T Ruff
A polygenic risk score predicts atrial fibrillation in cardiovascular disease. European heart journal (2022)
Jennifer A Rymer, Lisa A Kaltenbach, Eric D Peterson, David Joel Cohen, Gregory Y H Lip, Niteesh K Choudhry, Timothy D Henry, Christopher P Cannon, Tracy Y Wang
Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMIS. Journal of the American Heart Association 11 (20) (2022)
Robert S Rosenson, Mikhail Kosiborod, James A de Lemos, Qi Gao, Katherine E Mues, Shushama Alam, Deepak L Bhatt, Christopher P Cannon, Christie M Ballantyne, Robert S Rosenson, null null
Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). Clinical cardiology (2022)
Jennifer Y Barraclough, Jie Yu, Gemma A Figtree, Vlado Perkovic, Hiddo J Lambers Heerspink, Brendon L Neuen, Christopher P Cannon, Kenneth W Mahaffey, Aletta Elisabeth Schutte, Bruce C Neal, Clare Arnott
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial. Diabetes, obesity & metabolism 24 (6) (2022)
Matthew W Segar, Ahmed A Kolkailah, Robert Frederich, Annpey Pong, Christopher P Cannon, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard E Pratley, Chih-Chin Liu, Mario Maldonado, Jie Liu, Nilo B Cater, Ambarish Pandey, David Z I Cherney
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism 24 (9) (2022)
Karen D Corbin, Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, Francesco Cosentino, Robert Frederich, Jie Liu, Annpey Pong, Jianxin Lin, Nilo B Cater, Richard E Pratley
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease - analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin. Diabetes, obesity & metabolism (2022)
Hunter Nichols, Christopher P Cannon, Benjamin M Scirica, Naomi Deirdre Lakshmi Fisher
A remote hypertension management program clinical algorithm. Clinical cardiology (2022)
Christopher P Cannon
Statin intolerance: how common is it and how do we work with patients to overcome it? European heart journal 43 (34) (2022)
Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, Francesco Cosentino, Jie Liu, Annpey Pong, Ira Gantz, Robert Frederich, James P Mancuso, Richard E Pratley
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV. Diabetes, obesity & metabolism 24 (7) (2022)
Eri Toda Kato, David A Morrow, Jianping Guo, David D Berg, Michael A Blazing, Erin A Bohula, Marc P Bonaca, Christopher P Cannon, James A de Lemos, Robert P Giugliano, Petr Jarolim, Tibor Kempf, L Kristin Newby, Michelle L O'Donoghue, Marc A Pfeffer, Nader Rifai, Stephen D Wiviott, Kai C Wollert, Eugene Braunwald, Marc S Sabatine
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. European heart journal (2022)
David Z I Cherney, Francesco Cosentino, Richard E Pratley, Samuel Dagogo-Jack, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Chih-Chin Liu, Christopher P Cannon, null null
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV. Diabetes, obesity & metabolism 24 (6) (2022)
David Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, Francesco Cosentino, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Jie Liu, Shuai Wang, Christopher P Cannon, null null
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. Clinical cardiology 44 (8) (2021)
Michael Szarek, Deepak L Bhatt, Ph Gabriel Steg, Christopher P Cannon, Lawrence Alan Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra, Lars H Lund, Michel Komajda, Jeffrey M Testani, Christopher S Wilcox, Piotr Ponikowski, Renato Deláscio Lopes, Phillip Banks, Eshetu Tesfaye, Justin A Ezekowitz, Subodh Verma, Bertram Pitt, null null
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. Annals of internal medicine 174 (8) (2021)
David S Eccleston, Joseph M Kim, Jurien M Ten Berg, Phillippe Gabriel Steg, Deepak L Bhatt, Stefan H Hohnloser, Anne de Veer, Matias Nordaby, Corinna Miede, Takeshi Kimura, Gregory Yoke Hong Lip, Jonas Oldgren, Christopher P Cannon
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials). Clinical cardiology 44 (7) (2021)
Christopher T Sciria, Thomas M Maddox, Lucas Marzec, Benjamin Rodwin, Salim S Virani, Amarnath Annapureddy, James V Freeman, Ali O'Hare, Yuyin Liu, Yang Song, Gheorghe Doros, Yue Zheng, Jane J Lee, Ramesh Daggubati, Lina Vadlamani, Christopher P Cannon, Nihar R Desai
Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry. Clinical cardiology 43 (7) (2020)
Adam N Berman, David W Biery, Curtis Ginder, Olivia L Hulme, Daniel Marcusa, Orly Leiva, Wanda Y Wu, Avinainder Singh, Sanjay Divakaran, Jon Hainer, Alexander Turchin, James L Januzzi, Pradeep Natarajan, Christopher P Cannon, Marcelo F Di Carli, Deepak L Bhatt, Ron Blankstein
Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. Clinical cardiology 43 (11) (2020)
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod, David Z I Cherney, Jamie P Dwyer, Benjamin M Scirica, Clifford J Bailey, Rafael Díaz, Kausik K Ray, Jacob A Udell, Renato D Lopes, Pablo Lapuerta, Phillippe Gabriel Steg, null null
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. The New England journal of medicine 384 (2) (2020)
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino, Weichung J Shih, Ira Gantz, Steven G Terra, David Z I Cherney, Darren K McGuire, null null
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. The New England journal of medicine 383 (15) (2020)
Deepak L Bhatt, Michael Szarek, Phillippe Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra, Lars H Lund, Michel Komajda, Jeffrey M Testani, Christopher S Wilcox, Piotr Ponikowski, Renato D Lopes, Subodh Verma, Pablo Lapuerta, Bertram Pitt, null null
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New England journal of medicine 384 (2) (2020)
Johanna P Contreras, Kimberly N Hong, Javier Castillo, Lucas N Marzec, Jonathan C Hsu, Christopher P Cannon, Song Yang, Thomas M Maddox
Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. Clinical cardiology 42 (3) (2019)
Axel Åkerblom, Stefan K James, Tatevik G Lakic, Richard C Becker, Christopher P Cannon, Phillippe Gabriel Steg, Anders Himmelmann, Hugo A Katus, Robert F Storey, Lars Wallentin, W Douglas Weaver, Agneta Siegbahn, null null
Interleukin-18 in patients with acute coronary syndromes. Clinical cardiology 42 (12) (2019)